Glucosamine now available on prescription

Alateris (glucosamine) is the first prescription-only glucosamine product to receive a licence in the UK for the treatment of mild to moderate osteoarthritis (OA) of the knee.

The efficacy of glucosamine has been assessed in several clinical studies. In two long-term trials, glucosamine was reported to be more effective than placebo in reducing symptoms in patients with mild to moderate OA of the knee. It was also reported to be as effective as ibuprofen in two double-blind randomised four-week studies (n=178 and 200, respectively) in patients with OA of the knee.

Each Alateris tablet contains glucosamine 625mg. The daily dose is two tablets once daily. Relief of symptoms may not be experienced until after several weeks of treatment, and in some cases, even longer. If no relief of symptoms is experienced after two to three months, continued treatment with glucosamine should be re-evaluated.

Further information: Ransom 01462 437615

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Asthma drug hailed as first non-hospital treatment for COVID-19

Asthma drug hailed as first non-hospital treatment for COVID-19

Inhaled budesonide is the first widely available, inexpensive...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Under-30s to be offered alternative to AstraZeneca COVID-19 vaccine after reports of rare blood clots